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Abstract. This study tested if acetaminophen, N-methyl-D-glucamine dithiocarbamate (NMGDTC), 
deferoxamine, and combinations of these agents reduce excess iron content, prevent iron-induced pathology, 
reduce cardiac arrhythmias, and reduce mortality in iron-overloaded gerbils. Eight groups of 16 gerbils 
received iron dextran injections (ferric hydroxide dextran complex, 120 mg/kg, ip) or saline solution 
(controls) twice/wk for 8 wk. The 8 groups were treated every Monday, Wednesday, and Friday with one of 
the following: saline control, acetaminophen, 150 mg/kg, ip), acetaminophen (150 mg/kg, po),  deferoxamine, 
83 mg/kg, ip), NMGDTC (200 mg/kg, ip), or combinations of acetaminophen (75 mg/kg) with 
deferoxamine (42 mg/kg, each ip, separately) or  acetaminophen (75 mg/kg) with NMGDTC (100 mg/kg, 
each ip, separately). The treatments were given 4 hr after each iron injection on days when both iron 
administration and treatment occurred during iron overloading (8 wk) and were continued 4 wk thereafter. 
Echocardiography (ECHO) was used to evaluate iron-induced cardiac changes and detect arrhythmias. 
Acetaminophen and NMGDTC, or combinations thereof, reduced cardiac and hepatic excess iron content 
as measured by inductively coupled plasma atomic emission spectrometry (ICP-AES). Acetaminophen was 
effective whether administered po or ip. Acetaminophen treatment had a positive inotropic effect on cardiac 
function. Acetaminophen-deferoxamine combination conferred equal cardioprotection as acetaminophen 
or deferoxamine alone, was equally able to remove hepatic iron, and was superior to either acetaminophen 
or deferoxamine in removing cardiac iron from iron-overloaded gerbils. Acetaminophen-NMGDTC 
combination was also effective in removing cardiac and hepatic iron and protecting against iron-induced 
cardiac damage. ECHO evaluation of iron-overloaded, untreated gerbils demonstrated a high incidence of 
cardiac arrhythmias, usually PVCs (10/16 = 63%), and mortality prior to completion of the experiment 
(4/16 = 25%).  All treatments except deferoxamine, alone, reduced the incidence of cardiac arrhythmias 
and deaths. All treatments reduced iron-induced increases in hepatic and cardiac weights. This study 
demonstrates injection alternates that are equally or more effective than deferoxamine injections and shows 
oral acetaminophen to be effective in treatment of iron-overload and associated cardiac complications.
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Introduction
More than two million persons in the United States 
and up to one hundred million persons worldwide 
have some degree of iron-overload and tissue 
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accumulation of the metal [1]. It is estimated that 
nearly 40 million people worldwide have severe 
iron-overload. There are two major categories of 
conditions causing iron-overload: (a) hereditary 
hemochromotosis, an autosomal recessive disorder 
with a frequency of about 10% in individuals of 
European descent [2-4], and (b) various types of 
hemosiderosis involving RBC destruction and 
requiring blood transfusions [5]. In these cases, 
tissue iron levels progressively increase with age 
and may cause life-threatening complications. 
These include advanced liver disease and cirrhosis, 
diabetes mellitus due to iron accumulation in 
pancreatic islets with damage to beta cells, and 
cardiotoxicity due to iron deposits in myocytes, 
interstitial cells of the myocardium, and within the 
fibers of the conduction system. Cardiotoxic effects 
may be severe with cellular degeneration and 
fibrosis of the myocardium, disturbances of cardiac 
rhythm, and eventual death. Individuals with only 
mild to moderate elevations in tissue iron content 
appear to have increased risk for developing diabetes 
mellitus, heart disease, gastrointestinal cancers, 
and hematological malignancies [1].
 Treatment with phlebotomy results in clinical 
improvement of subjects with established elevations 
in tissue iron burden and, if used as a preventative 
therapy, may lessen or ameliorate organ damage 
and allow normal life expectancy [1,6]. However, 
this treatment requires weekly removal of up to a 
liter of whole blood for a year or longer, followed by 
lifetime maintenance phlebotomy. Therapy with 
currently approved chelating agents is presently a 
poor substitute for phlebotomy and is used mainly 
in patients with secondary hemochromatosis or 
hemosiderosis. Deferoxamine (Desferal,® Novartis), 
deferiprone (L1), and deferasirox (Exjade,®  Novartis) 
are the major chelating agents currently used to 
treat iron overload. Deferoxamine has been used 
for many years, but it must be administered by 
parenteral routes and is associated with adverse 
effects and low compliance [5, 7].  L1 (1, 2-dimethyl-
3-hydroxypyridin-4-one), a once promising orally 
active iron chelator, appears to be ineffective [8] or 
contraindicated [9] in many patients.  Deferasriox 
has recently been approved to treat iron-overloaded 
patients. It is orally effective and its long half-life 
enables once-daily dosing [10,11]. At present there 
is a great clinical need for additional, orally active 
iron chelating drugs for treating iron overload.  
 Previous studies in our laboratory [12,13] 
demonstrated that injections of acetaminophen 
and deferoxamine are equally effective in reducing 
cardiac excess iron content in iron-overloaded 
gerbils, and preventing cardiac structural and 
functional changes. This paper reports concurrent 
studies of iron-overloaded gerbils, not published in 
the original paper [12], which show that injections 
of acetaminophen, deferoxamine, or N-methyl-D-
glucamine dithiocarbamate (NMGDTC), as well 
as combinations of acetaminophen with deferox-
amine or NMGDTC reduce the excess iron content 
in heart and liver and protect against iron-induced 
cardiotoxicity in iron-overloaded gerbils. 
Materials and Methods
Chemicals. Ferric hydroxide dextran complex (Sigma 
Chemical Co., St Louis, MO) dissolved in NaCl solution 
(1%, w/v) was used for iron overloading.  The treatment agents 
were: (a) acetaminophen (Sigma), (b) deferoxamine  methane-
sulfonate (Sigma), and (c) NMGDTC, synthesized as 
described [14] and supplied by Dr. Mark M. Jones (Vanderbilt 
University, Nashville, TN). 
Animals. Mongolian golden gerbils (Hilltop Laboratories, 
Scottsdale, PA; male; age 12 wk; average initial weight ~60 g) 
were housed on wood chip bedding in plastic tubs at 23 ± 2°C 
in rooms with a 12 hr light/dark cycle. Purina gerbil chow 
and tap water were available ad libitum. All procedures with 
animals were approved by the Marshall University Institutional 
Animal Care and Use Committee.
Treatments. The  gerbils were divided into 8 groups of 16 
animals: (a) saline controls (SC) received injections of 1% 
saline (0.15 ml/kg, ip) twice/wk for 8 wk; (b) iron-overloaded 
animals (IO) received similar injections of iron dextran in 1% 
saline (120 mg/kg, ip, twice/wk); (c) iron-overloaded treated 
with acetaminophen (150 mg/kg, ip, IOAi); (d) iron-
overloaded treated with acetaminophen (150 mg/kg, po, 
IOAo); (e) iron-overloaded treated with deferoxamine (83 
mg/kg, ip, IODF); (f ) iron-overloaded treated with NMGDTC 
(200 mg/kg, ip, IONMG); (g) iron-overloaded  treated with 
half-doses of acetaminophen (75 mg/kg) and deferoxamine 
(42 mg/kg) given separately as ip injections (IOA0.5NMG0.5); 
and (h) iron-overloaded  treated with half-doses of acetamino-
phen (75 mg/kg) and NMGDTC (100 mg/kg) given 
separately as ip injections (IOA0.5DF0.5). The saline  and 
iron dextran solutions were injected twice/wk for 8 wk. The 
acetaminophen, deferoxamine, NMGDTC, and combinations 
were administered thrice/wk (every Monday, Wednesday, and 
Friday). When an iron dextran injection and drug treatment 
fell on the same day, the treatment was administered 2 to 4 hr 
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after the iron dextran. The treatments followed this schedule 
for 8 wk and were continued for an additional 4 weeks (total 
of 12 wk of treatment). Echocardiograms were performed on 
gerbils at 12 wk after the last treatment.
Echocardiography (ECHO). ECHO studies were conducted 
on gerbils anesthetized by ip injection of a 2:1 (v/v) mixture of 
ketamine HCl (100 mg/ml) and xylazine (20 mg/ml). The 
ECHO studies used a Phillips Sonos 5500 echocardiogram 
with a S12 transducer (frequency range 8-12 MHz) as 
described previously [12]. Echocardiographic images were 
obtained including two-dimensional, pulse-wave Doppler 
and M-mode images. Functional and structural parameters 
were evaluated as described previously [12,14].
Tissue iron analysis. After completion of the echocardiograms, 
the gerbils were euthanized by inhalation of CO2. The hearts 
and livers were removed by dissection, weighed, frozen in 
liquid nitrogen, and stored at -70°C until analysis. Whole 
hearts and liver samples (300-400 mg) were digested at 37°C 
for 6 or 17 hr in glass digestion tubes containing concentrated 
ultrapure nitric and perchloric acids (30:70, v/v, total volume 
10 ml).  A 1.67 mg/L iron solution was used as a digestate 
control. Yttrium solution (1,000 mg/L) in 2% HNO3 was 
added to each tube and served as an internal standard (final 
concentration, 1.67 mg/L). After digestion, 5.0 ml of each 
digestate was transferred to a 50 ml volumetric flask and 
brought to volume with 2% HNO3 (ultrapure).  The solutions 
were filtered through 0.22 µm syringe-driven filter units 
(Millipore). Tissue iron concentrations were determined by 
inductively coupled plasma/atomic emission spectrometry 
(ICP-AES), using an Optima 2100 apparatus (Perkin-Elmer, 
Norwalk, CT; 238 and 204 nm). Standard curves (0 to 1; 0 to 
10; 0 to 100 mg Fe/L) were prepared depending on the tissue 
iron concentrations [15-18] and the results were reported as 
mg Fe/entire liver or µg Fe/entire heart.
Statistics. Data were expressed as mean ± SD. Statistical 
analyses were performed using Sigma Stat software (Jandel 
Corp., San Rafael, CA). Differences among the means of the 
groups were assessed by two-way ANOVA, followed by 
Tukey’s test. Values of p ≤0.05 were considered significant.
Results
Effects on cardiac and liver iron. Injections ip of 
acetaminophen, deferoxamine, or NMGDTC, 
alone, and acetaminophen-deferoxamine or acet-
aminophen-NMGDTC combinations reduced the 
excess cardiac and hepatic iron contents (Fig. 1). 
Oral administration of acetaminophen also reduced 
tissue iron content and ameliorated cardiac effects. 
The post-treatment hepatic iron contents were: SC, 
0.24 ± 0.02  mg; IO, 49.05 ± 1.46 mg; IOAi, 37.40 
± 6.78 mg; IOAo, 33.98 ± 6.34 mg; IODF, 20.20 ± 
1.64 mg; IONMG, 18.31 ± 1.07 mg; IOA0.5-
NMG0.5, 18.93 ± 1.93 mg ; IOA0.5DF0.5, 18.24 ± 
1.04 mg. The post-treatment cardiac iron contents 
were: SC, 15.11 ± 11.77 µg; IO, 243.36 ± 51.08 µg; 
IOAi, 130.38 ± 29.58 µg; IOAo, 131.76 ± 26.62 
µg; IODF, 110.50 ± 7.47 µg; IONMG, 106.34 ± 
10.59 µg; IOA0.5NMG0.5, 101.39 ± 12.36 µg; 
IOA0.5DF0.5, 88.53 ± 9.21 µg. The average post-
treatment cardiac iron concentrations per g of heart 
were: SC, 43.17 ± 27.81 µg; IO, 552.27 ± 58.12 µg; 
IOAi, 395.09 ± 88.10 µg; IOAo, 387.52 ± 66.44 
µg; IODF, 324.99 ± 23.95 µg; IONMG, 304.00 ± 
17.40  µg; IOA0.5NMG0.5,  316.84 ± 59.04 µg; 
IOA0.5DF0.5, 268.27 ± 25.38 µg.
 The best results for cardiac iron removal were 
produced by the ip injection combination of half-
doses of acetaminophen (75 mg/kg) and deferox-
amine (42 mg/kg) (IOA0.5DF0.5), which removed 
Fig, 1. The iron content of liver (mg/entire liver) (panel A) and 
heart (µg/entire heart) (panel B) of saline controls (n = 13), 
and gerbils that were iron overloaded (IO, n = 13), 
acetaminophen injected (IOAi, n = 9), acetaminophen 
administered by oral gavage (IOAo, n = 10), deferoxamine 
injected (IODF, n = 7), NMGDTC injected (IONMG, n = 
8), acetaminophen (half-dose) plus NMGDTC (half-dose) 
injected (IoAiNMG, n = 8), and  acetaminophen (half-dose) 
plus deferoxamine (half-dose) injected (IOAiDF, n = 8). The 
* or + indicate significant differences (p <0.05) from the 
controls or iron overloaded gerbils, respectively. 
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Table 1.  Echocardiographic evaluation of cardiac structural parameters in gerbils.
         
Group N IVSd IVSs LVIDd LVIDs LVPWd LVPWs RV
  (cm) (cm) (cm) (cm) (cm) (cm) (cm)
Control 16 0.09 ± 0.01 0.15 ± 0.01 0.43 ± 0.01 0.27 ± 0.01 0.11 ± 0.01 0.14 ± 0.01 0.14 ± 0.01
IO 15 0.13 ± 0.01* 0.19 ± 0.01* 0.53 ± 0.02* 0.35 ± 0.01* 0.17 ± 0.01* 0.19 ± 0.01* 0.20 ± 0.01*
IOAi 9 0.09 ± 0.01+ 0.14 ± 0.01+ 0.44 ± 0.01+ 0.30 ± 0.01*,+ 0.11 ± 0.01+ 0.15 ± 0.01+ 0.12 ± 0.01+
IOAo 10 0.09 ± 0.02+ 0.15 ± 0.02+ 0.48 ± 0.02+ 0.31 ± 0.02*,+ 0.10 ± 0.01+ 0.16 ± 0.02+ 0.12 ± 0.02+
IODF 7 0.10 ± 0.01+ 0.15 ± 0.01+ 0.43 ± 0.02+ 0.27 ± 0.01+ 0.12 ± 0.01+ 0.15 ± 0.01+ 0.14 ± 0.01+
IONMG 8 0.11 ± 0.01+ 0.16 ± 0.02+ 0.44 ± 0.02+ 0.30 ± 0.03+ 0.12 ± 0.02+ 0.16 ± 0.02+ 0.15 ± 0.03+
IOAiNMG 8 0.08 ± 0.02+ 0.13 ± 0.02+ 0.49 ± 0.06 0.32 ± 0.04 0.12 ±  0.02+ 0.16 ± 0.02+ 0.11 ± 0.01+
IOAiDF 8 0.10 ± 0.01+ 0.15 ± 0.01+ 0.46 ± 0.05 0.32 ± 0.03 0.12 ± 0.02+ 0.15 ± 0.02+ 0.12 ± 0.03+
 
An asterisk (*) or cross (+) indicates significant difference (p <0.05) from control and iron-overloaded (IO) gerbils, respectively. 
N, number of gerbils in the group;  IVSd,  diastolic LV septal thickness;  IVSs,  systolic LV septal thickness;  LVIDd,  diastolic 
LV internal thickness;  LVIDs, systolic LV internal thickness;  LVPWd, diastolic LV posterior wall thickness; LVPWs, systolic 
LV posterior wall thickness; RV,  RV diastolic internal dimension.
Table 2. Echocardiographic evaluation of cardiac functional parameters in gerbils.
Group EF FS AV Max PV Max MV Max MV Max
 (%) (%) (cm/sec) (cm/sec) (cm/sec) (cm/sec)
Control 77.5 ± 1.5 40.4 ± 1.5 47.2 ± 2.5 48.9 ± 3.2 41.0 ± 3.9 40.3 ± 2.6
IO 60.6 ± 1.8* 27.9 ± 1.3* 49.8 ± 2.4 52.9 ±  4.2 38.0 ±  3.7 38.1 ± 3.1
IOAi 72.5 ± 1.7*,+ 35.0 ± 2.0*,+  70.4 ± 4.0*,+ 66.2 ± 4.4*,+ 50.7 ± 2.9*,+ 51.0 ± 4.0*,+
IOAo 76.4 ± 1.7+ 39.3 ± 1.3+ 58.6 ± 3.3*,+ 58.1 ± 4.0* 44.3 ± 3.4 37.0 ± 1.8
IODF 67.1 ± 1.1*,+ 34.1 ± 2.4*,+ 53.4 ± 3.9 47.6 ± 3.2 39.8 ± 3.2 37.6 ± 2.3
IONMG 69.6 ± 5.0*,+ 34.0 ± 3.7*,+ 54.9 ± 9.6 45.9 ± 6.1 ---------- ----------
IOAiNMG 70.4 ± 4.0* 34.8 ± 3.2* 60.2 ± 8.2+ 57.1 ± 5.0 ----------          ----------          
IOAiDF 64.8 ± 10.4* 29.7 ± 7.3* 48.6 ± 6.6 44.7 ± 5.0 ---------- ----------
An asterisk (*) or cross (+) indicates significant difference (p <0.05) from control and iron overloaded (IO) gerbils, respectively. 
EF, ejection fraction; FS,  left ventricular fractional shortening during systole; AV Max, maximal aortic valvular blood flow 
velocity; PV Max, maximal pulmonary valvular blood flow velocity; MV Max, maximal mitral valvular blood flow velocity; TV 
MAX, maximal tricuspid valvular blood flow velocity.
Table 3:   Body weights, liver weights/body weights, and heart weights/body weights of the gerbils.
Group Body wt. Liver wt./body wt. Heart wt./body wt.
 (g) (%) (%)
Control 83.7 ± 2.2 3.77 ± 0.46 0.41 ± 0.03
IO 66.9 ± 2.6 7.80 ± 0.86* 0.65 ± 0.12*
IOAi 85.3 ± 2.4 5.44 ± 0.36*,+ 0.43 ± 0.04+
IOAo 84.2 ± 2.3 5.14 ± 0.20*,+ 0.40 ± 0.01+
IODF 92.6 ± 5.6 4.78 ± 0.28*,+ 0.37 ± 0.01+
IONMG  85.5 ± 2.7 5.23 ±  0.22*,+ 0.39 ± 0.03+
IOAiNMG 84.4 ± 4.5 5.11 ± 0.12*,+ 0.39 ± 0.03+
IOAiDF    92.3 ± 2.3 4.25 ± 0.05*,+ 0.33 ± 0.02*,+ 
Average group and organ/body weights at the end of the experiments. An asterisk (*) or cross (+) indicates significant difference 
(p <0.05) from control and iron overloaded (IO) gerbils, respectively.  See Materials and Methods for abbreviations.
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significantly more cardiac iron (p <0.05) than was 
removed by full-dose injections of either acetamino-
phen (150 mg/kg) or deferoxamine (83 mg/kg) 
alone. The cardiac iron removal produced by the 
combination of half-doses of acetaminophen and 
NMGDTC (100 mg/kg) (IOA0.5EY0.5) was not 
significantly greater than that removed by full-
doses of either agent alone. Combinations of half-
doses of acetaminophen and deferoxamine 
(IOA0.5DF0.5) removed slightly more hepatic iron 
than either agent alone, but the results were not 
significant when compared to deferoxamine alone.
Echocardiographic studies. The ECHO results for 
control, iron-overloaded, iron-overloaded-acet-
aminophen-treated and iron-overloaded-deferox-
amine-treated gerbils are reported in Tables 1 and 
2 and in the earlier publication [12].  Iron-
overloading affected structural parameters of the 
heart, increased total cardiac weight, and produced 
cardiac hypertrophy as shown by increased septal, 
left ventricular, and right ventricular wall 
thicknesses. These changes were abrogated by treat-
ments with acetaminophen or its combinations.  
 Cardiac function was evaluated by measure-
ments of ejection fraction (EF) and left ventricular 
shortening during systole (FS), as well as blood 
flow velocities through cardiac valves. Hearts from 
iron-overloaded gerbils demonstrated reductions in 
EF and FS consistent with appreciable compromise 
of cardiac function.  Acetaminophen, given orally 
or by injection, prevented these changes or restored 
cardiac function to values similar to untreated 
controls. An interesting result of acetaminophen 
treatment was increased blood flow rates through 
cardiac valves (aortic, pulmonary, mitral, tricuspid) 
(Table 2), which suggest a positive inotropic effect 
conferred by injected acetaminophen. This finding 
may be important and merits further study.  
 ECHO studies were concurrently completed 
for the iron-overloaded-acetaminophen (75 mg/kg) 
plus deferoxamine (42 mg/kg), iron-overloaded–
NMGDTC (200 mg/kg), and iron-overloaded-
NMGDTC (100 mg/kg) plus deferoxamine (42 
mg/kg) groups.  The results demonstrate cardio-
protection against the iron-induced functional and 
structural changes similar to the protection 
provided by acetaminophen alone (Tables 1 & 2). 
Arrhythmias and mortality. During the total 
period of observation of the 16 saline controls (SC), 
none developed cardiac arrhythmias (ECHO 
studies) and there were no deaths.  Of 16 iron-
overloaded gerbils, 10 developed significant cardiac 
arrhythmias, ie, chiefly premature ventricular 
contractions (PVCs), and 4 of the 16 gerbils died 
after completion of ECHOs and prior to the end of 
the experiment. Nine of 16 iron-overloaded gerbils 
treated by acetaminophen, ip (IOAi) were evaluated 
by ECHO and showed 0 cardiac arrhythmias 
(ECHO) and 1 death. Ten of 16 iron-overloaded 
gerbils treated orally with acetaminophen (IOAo) 
were evaluated by ECHO and demonstrated 1 
animal with cardiac arrhythmia (PVCs) and 0 
deaths.  Seven of the 16 iron-overloaded gerbils 
treated with deferoxamine ip were evaluated by 
ECHO and 3 animals showed cardiac arrhythmias 
(PVCs), and died prior to the end of the experiment. 
Eight of 16 NMGDTC injected gerbils were 
evaluated by ECHO and there was 1 animal with 
cardiac arrhythmia and 1 death (same animal). 
Eight of 16 animals treated with half-doses of 
acetaminophen plus half-doses of deferoxamine 
were evaluated by ECHOed and 1 animal 
demonstrated cardiac arrhythmia but 0 deaths. 
Eight of 16 gerbils treated with half-doses of 
acetaminophen plus half-doses of NMGDTC and 
evaluated by ECHO showed 1 animal with cardiac 
arrhythmia but there were 0 deaths. All treatments 
except deferoxamine produced appreciable 
reductions in the incidence of iron-induced cardiac 
arrhythmias and mortality.
 Iron overloading was very toxic to the gerbils. 
Iron overloading caused a high incidence of 
arrhythmias (10/16), mortality (4/16), suppression 
of weight gain, and increased heart and liver weights 
as shown in Table 3.  Initial body weights of the 
gerbils averaged about 60 g.  All groups except the 
untreated iron-overloaded gerbils showed weight 
increases of 20 g or more at 12 wk.  The untreated 
iron-overloaded group gained an average of ~7 g.
Discussion
Acetaminophen is a frequently used non-steroidal 
anti-inflammatory analgesic agent. Deferoxamine 
is an established iron-removing agent with great 
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effectiveness when administered parenterally. 
NMGDTC is a substituted dithiocarbamate (LD50 
>2 g/kg in mice) that has been reported to combat 
the platinum toxicity seen in the use of cisplatin in 
cancer chemotherapy [19]. It has also been shown 
to have iron-chelating ability [20,21]. Results of 
this study demonstrate that it has a similar ability 
as deferoxamine and acetaminophen in removing 
cardiac and liver iron from iron-overloaded gerbils. 
NMGDTC was able to prevent or reverse iron-
induced cardiac structural changes and improve 
iron-induced decline in EF and FS (Tables 1 & 2). 
However, NMGDTC is unstable in an acid (gastric) 
environment so that it has limited effectiveness 
when administered orally.
 Injections of acetaminophen, acetaminophen-
deferoxamine combination, NMGDTC, or acet-
aminophen-NMGDTC combination reduced the 
tissue iron contents without producing appreciable 
signs of toxicity or drug-related deaths. This is 
consistent with a study in rats in which daily oral 
(gavage) doses of acetaminophen (200 mg/kg for 
200 days) failed to induce any significant changes 
when compared to controls [22].  In a similar study, 
male C57BL/6J mice received acetaminophen (30 
or 300 mg/kg). The higher dose up-regulated 6 
genes and down-regulated 18 genes when evaluated 
24 hr after the injection of acetaminophen. The 
acetaminophen effects on gene expression serve as 
markers of mild hepatotoxicity, but no histological 
findings of hepatic necrosis or other hepatotoxicity 
were noted [23]. Results of our acetaminophen-
deferoxamine or acetaminophen-NMGDTC 
combination studies show that the lower dose of 
acetaminophen is effective in combinations, thus 
providing a greater safety margin for the drug in 
treatments. 
 A previous study demonstrated that injections 
of acetaminophen and deferoxamine are equally 
effective in reducing cardiac excess iron content 
and preventing cardiac structural and functional 
changes as assessed by ECHO studies [12]. In the 
present study, the ECHO techniques demonstrated 
that acetaminophen-deferoxamine combination 
conferred equal cardioprotection as acetaminophen 
or deferoxamine alone. The combination 
demonstrated a similar ability to remove hepatic 
iron, and superior ability to either acetaminophen 
or deferoxamine in removing cardiac iron from 
iron-overloaded gerbils. NMGDTC alone and 
acetaminophen-NMGDTC combination were as 
effective as deferoxamine in removing hepatic and 
cardiac iron (Fig. 1). NMGDTC was particularly 
impressive in preventing iron-induced cardiac left 
ventricular and right ventricular structural changes 
(Table 1) to a degree similar to that produced by 
acetaminophen. Half-dose combination of injected 
acetaminophen and NMGDTC reduced iron-
induced alterations in right ventricular structure 
but were slightly less effective than NMGDTC or 
acetaminophen in preventing left ventricular 
structural changes. The finding that NMGDTC 
reduced or prevented iron-induced cardiac 
functional changes while removing excess cardiac 
and hepatic iron suggests that this compound is a 
potential agent for treating iron overload. 
 Congestive cardiomyopathy is the most 
common defect that occurs with iron overload, but 
pericarditis, restrictive cardiomyopathy, and angina 
without coronary artery disease have been reported 
[24-27].  Iron deposition in the bundle of His and 
the Purkinje system produces conduction defects 
and may cause fatal arrhythmias [28,29].  Physical 
examination may fail to disclose cardiac toxicity, 
but cardiac failure may occur suddenly, with rapid 
deterioration without medical intervention. 
Biventricular heart failure produces pulmonary 
congestion, peripheral edema, and hepatic 
engorgement. Vigorous iron extrication can reverse 
this potentially lethal complication [30]. 
 Echocardiography in children and radionuclide 
ventriculography in adults are the most useful non-
invasive diagnostic techniques. Exercise radionuclide 
ventriculograms are particularly sensitive in the 
detection of cardiac dysfunction in patients with 
iron overload [31]. These techniques can be used 
periodically to evaluate therapeutic responses 
during treatments such as chelation. In our study, 
echocardiography and electrocardiography were 
used to follow cardiac improvement induced by the 
acetaminophen or combination treatments. 
Electrocardiography was used in conjunction with 
echocardiography to detect the development and 
prevention or reversal of iron-induced cardiac 
arrhythmias.  A strong correlation exists between 
the cumulative number of blood transfusions and 
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functional cardiac derangements in children with 
thalassemia [32,33], so that the echocardiographic 
abnormalities correlate roughly with the number of 
transfusions or degree of cardiac iron overload.
 Effects of iron on cardiomyocyte contractility 
have been documented. Iron salts added to cultures 
of chick cardiac cells poison the cells and impede 
their ability to contract spontaneously. 
Deferoxamine restores myocyte contractility 
through chelation of extracellular and intracellular 
iron [34].
 Cardiac dysfunction can occur with little tissue 
iron deposition. The total quantity of iron is less 
important than the unbound “toxic” iron subset. 
The concentration of unbound iron in tissues is 
extremely small and virtually impossible to 
measure. This “toxic” iron is the component bound 
and neutralized by iron chelators. Therefore, cardiac 
damage is best prevented in patients with 
transfusional iron overload by maintaining a 
constant low level of chelator in the circulation and 
tissues [12,35]. Early use of deferoxamine in an 
amount proportional to the transfusional iron load 
reduces the body iron burden and helps protect 
against diabetes mellitus, cardiac disease, and early 
death in patients with thalassemia major [36]. 
 In conclusion, this study shows that NMGDTC 
is capable of reducing cardiac and liver iron content 
in iron-overloaded gerbils, combating iron-induced 
cardiac structural and functional changes, and 
reducing iron-induced hepatic weight increases. 
NMGDTC is effective when administered alone, 
or combined with acetaminophen. Acetaminophen 
shares with deferoxamine the abilities to remove 
cardiac and hepatic iron, restore contractility, and 
prevent iron-induced cardiac structural and 
functional deterioration. Acetaminophen offers a 
number of distinct advantages: (a) it provides a 
potential treatment of iron overload with an orally 
effective agent; (b) its iron-removing effectiveness is 
equal to or greater than established agents such as 
deferoxamine, which has to be injected; (c) 
acetaminophen can be used concurrently with 
other agents with additive or synergistic effects, 
allowing the use of lower doses of the agents; (d) 
acetaminophen protects the heart against iron-
induced cardiac structural changes by preventing 
iron-induced increases in total heart mass and 
preventing or reversing iron-induced increases in 
heart LV and RV thicknesses; (e) acetaminophen 
prevents or reverses iron-induced impairment in 
cardiac function, as shown by restoration of FS and 
EF to values similar to saline controls; (f) 
acetaminophen appears to decrease the incidence 
of life-threatening  arrhythmias, a common cause 
of death, and may combat other iron-induced 
cardiac complications such as congestive 
cardiomyopathy; and (g) acetaminophen may have 
positive inotropic effects on cardiac function, a 
finding that should be investigated  further.
 Based on our previous work [12], we speculate 
that acetaminophen may provide cardioprotection 
by two different but related mechanisms: its 
antioxidant effects and by removal of excess cardiac 
iron concentrations. Deferoxamine and NMGDTC 
may provide cardioprotection by the same two or 
by different mechanisms. The iron-removing ability 
of acetaminophen-deferoxamine combination is 
superior to that of either agent alone. The anti-
oxidant characteristics of acetaminophen might 
provide cardioprotection and prevent tissue or 
organ damage in various conditions that involve 
increased iron concentrations and that induce the 
release of free radicals and other oxidants [1].  It is 
interesting to speculate that combinations of 
acetaminophen and deferasirox, a recently approved 
oral agent for treating transfusional iron overload, 
both orally effective, might offer advantages over 
that of either agent. Our future studies may address 
this possibility.  
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